In order to evaluate the efficacy and tolerability of oxycodone in moderate-severe cancer-related pain Igf2 we conducted a systematic review of randomized controlled tests (RCTs). of 613 malignancy individuals with moderate-severe pain. The meta-analysis results showed that oxycodone was statistically superior to other strong opioids based on pain intensity scores following treatment [weighted mean difference (WMD) 0.25 95 CI 0.05 P=0.01; WMD ?1.30; 95% CI ?1.55-1.05; P<0.001 respectively]. In addition there were statistically significant variations between oxycodone and additional strong opioids in cancer-related pain on the obvious effective rate and the overall effective rate (OR 2.03 95 CI 1.4 P=0.0002; OR 1.94 95 CI 1.09 P=0.02 respectively). Compared with other strong opioids nausea and constipation occurred significantly less regularly with the use of oxycodone for cancer-related pain (OR=0.52 95 CI=0.32-0.85 P=0.009; OR= 0.55 95 CI= 0.35-0.87 P= 0.01; respectively). In conclusion this meta-analysis confirms the effectiveness and tolerability of oxycodone are superior to those of additional strong opioids including morphine sulfate codeine and tramadol assisting its use as an opioid for cancer-related pain. Keywords: oxycodone cancer-related pain randomized controlled trial meta-analysis Intro Cancer-related pain occurs in more than 80% of malignancy patients prior to mortality (1). For individuals with advanced malignancy pain was described as moderate-severe in approximately 40-50% and as very severe in 25-30% (2). Approximately 70% of individuals with moderate-severe cancer-related pain require opioid analgesics during the course of the disease (3). Cancer-related pain may be handled with the various pharmacological and non-pharmacological methods currently available but this is not usually effective and several patients continue to suffer pain (4). Since the 1980s treatment of cancer-related pain has been based on the World Health Business (WHO) analgesic ladder. However up to half of individuals received inadequate analgesia and 30% of individuals did not get appropriate drugs for his or her pain (5). Relating to WHO recommendations opioid analgesics are the mainstay of analgesic therapy and are classified according to their ability to control pain from slight to mild-moderate to moderate-severe intensity (6). Due to the intolerable adverse effects associated with opioids approximately 20% of malignancy patients may need to switch to an alternative opioid (7-9). Morphine oxycodone methadone hydromorphone fentanyl alfentanyl buprenorphine heroin levorphanol and oxymorphone are the most widely used strong opioids for moderate-severe cancer-related pain in China. Oxycodone is definitely a semisynthetic derivative of morphine. The effectiveness and tolerability of oxycodone are similar to morphine assisting its use as Torin 1 an opioid for moderate-severe cancer-related pain (10). It has been in medical use since 1917 but patterns of use have differed worldwide perhaps reflecting the lack of medical studies investigating its effectiveness (11). In the last ten years in China the consumption of oxycodone has been increasing markedly. However there is no evidence from high-quality comparative studies that oxycodone is definitely superior to morphine and additional opioids in terms of effectiveness and tolerability (7). The aim of this study was to evaluate the effectiveness and tolerability of oxycodone in moderate-severe cancer-related pain in China Torin 1 by conducting a meta-analysis from all qualified randomized controlled tests (RCTs) published to date. Materials and methods Literature search We performed an electronic search of the Cochrane library PubMed Embase and CBM databases to retrieve studies linking the effectiveness and tolerability of oxycodone in moderate-severe cancer-related pain in China available up to August 2011 without language restrictions using the following search tools: (‘oxycodone’ ‘oxycodeinon’ ‘oxycone’ ‘dihydrohydroxycodeinone’ ‘pancodine’ or ‘oxycodone hydrochloride’) (‘pain’ ‘ache’ or ‘aches’) (‘neoplasms’ ‘malignancy’ or ‘tumor’) (‘therapeutics’ or ‘treatment’) and (‘randomized controlled tests’ ‘controlled medical tests randomized’ or ‘medical tests randomized’). The research lists of major textbooks evaluations and included content articles were recognized through manual searches to find additional potentially eligible studies. If more Torin 1 than one article was published from the same author using the same case series we selected the research with the largest sample size. Inclusion and exclusion criteria In order Torin 1 to be eligible for inclusion with this meta-analysis the following criteria were founded: i) Clinical RCTs that.